title: Cytokine-enhanced vaccine and interferon-β plus suicide gene as combined therapy for spontaneous canine sarcomas.
abstract: Eleven soft tissue- and five osteosarcoma canine patients were subjected to: (i) periodic subcutaneous injection of irradiated xenogeneic cells secreting hGM-CSF and hIL-2 mixed with allogeneic or autologous tumor homogenates; and (ii) injections of cIFN-β and HSVtk-carrying lipoplexes and ganciclovir, marginal (after surgery) and/or intratumoral (in the case of partial tumor resection, local relapse or small surface tumors). This treatment alone (4 patients) or as surgery adjuvant (12 patients), was safe and well tolerated. In those patients presenting local disease (6/11), the suicide gene plus cIFN-β treatment induced local antitumor activity evidenced by the objective responses (3 complete, 2 partial) and stable diseases (2). In addition, the treatment prevented or delayed local relapse, regional metastases (lymph nodes developed only in 3/16) and distant metastases (0/16), suggesting a strong systemic antitumor immunity. The most encouraging result was the long survival times of 10 patients (>1 year, with good quality of life).
authors.affiliation: Unidad de Transferencia Genética, Instituto de Oncología Ángel H Roffo, Universidad de Buenos Aires, Argentina.
authors.forename: Liliana M E
authors.initials: LM
authors.lastname: Finocchiaro
authors.forename: Marcela S
authors.initials: MS
authors.lastname: Villaverde
authors.forename: María L
authors.initials: ML
authors.lastname: Gil-Cardeza
authors.forename: María D
authors.initials: MD
authors.lastname: Riveros
authors.forename: Gerardo C
authors.initials: GC
authors.lastname: Glikin
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000662:veterinary; D016207:Cytokines / Q000235:genetics*; D004283:Dog Diseases / Q000601:surgery / Q000628:therapy*; D004285:Dogs; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage; D015316:Genetic Therapy / Q000662:veterinary*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics; D016899:Interferon-beta / Q000235:genetics*; D007376:Interleukin-2 / Q000235:genetics; D008297:Male; D012509:Sarcoma / Q000601:surgery / Q000628:therapy / Q000662:veterinary*; D018139:Simplexvirus / Q000201:enzymology; D013937:Thymidine Kinase / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D016207:Cytokines; D007376:Interleukin-2; D016899:Interferon-beta; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D013937:Thymidine Kinase; D015774:Ganciclovir